Health Care & Life Sciences » Pharmaceuticals | Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co. Ltd. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
340,611
333,446
364,316
347,956
353,380
346,531
Cost of Goods Sold (COGS) incl. D&A
146,913
149,971
163,244
143,346
137,408
127,691
Gross Income
193,698
183,475
201,072
204,610
215,972
218,840
SG&A Expense
141,720
147,133
157,307
153,142
153,763
160,049
EBIT
51,773
36,173
43,765
-
62,209
58,791
Unusual Expense
4,434
2,714
4,057
286
7,279
794
Non Operating Income/Expense
6,081
643
5,030
3,970
5,303
13,942
Interest Expense
259
145
59
400
391
594
Pretax Income
49,773
27,245
41,400
42,877
55,849
73,438
Income Tax
19,604
11,347
11,626
12,427
12,950
19,025
Consolidated Net Income
30,169
15,898
29,774
30,450
42,899
54,414
Net Income
30,078
15,898
29,774
30,450
42,899
54,414
Net Income After Extraordinaries
30,078
15,898
29,774
30,450
42,899
54,414
Net Income Available to Common
30,078
15,898
29,774
30,450
42,899
54,414
EPS (Basic)
54.95
29.05
54.40
55.64
78.38
99.40
Basic Shares Outstanding
547
547
547
547
547
547
EPS (Diluted)
54.91
29.02
54.36
55.59
78.30
99.30
Diluted Shares Outstanding
548
548
548
548
548
548
EBITDA
84,942
72,884
80,324
75,252
84,241
81,012
Other Operating Expense
205
169
-
-
-
-
Non-Operating Interest Income
775
629
459
477
486
601
Minority Interest Expense
91
-
-
-
-
-
Equity in Affiliates (Pretax)
4,163
6,055
3,738
12,351
4,478
97

About Kyowa Hakko Kirin Co.

View Profile
Address
Otemachi Financial City Grand Cube
Tokyo Tokyo 100
Japan
Employees -
Website http://www.kyowa-kirin.co.jp
Updated 07/08/2019
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension.